The occurrence of depression is higher in patients with chronic liver disease (CLD) than that in the general population. The mechanism described in previous studies mainly focused on inflammation and stress, which not only exists in CLD, but also emerges in common chronic diseases, leaving the specific mechanism unknown. This review was to summarize the prevalence and risk factors of depression...

the purpose of this study was to determine a simple and sensitive test for clinical diagnosis of various hepatic diseases. therefore y-glutamyltranspeptidase (y** gt), aspartate aminotransferase (asat), alanine aminotr¬ansferase (alat) and alkaline phosphatase (alp) levels were measured in 29 healthy adults and 88 sera with various liver diseases. table i represents the results, according to wh...

The aim of the study was to identify the prevalence of HFE gene mutations in Czech patients with chronic liver diseases and the influence of the mutations on iron status. The presence of HFE gene mutations (C282Y, H63D, and S65C) analyzed by the PCR-RFLP method, presence of cirrhosis, and serum iron indices were compared among 454 patients with different chronic liver diseases (51 with chronic ...

Chronic liver disease, one of the most common diseases, typically arises from nonalcoholic fatty liver disease, alcoholic liver disease, chronic viral hepatitis, or hepatocellular carcinoma. Therefore, there is a pressing need for improved treatment strategies. Korean Red Ginseng has been known to have positive effects on liver disease and liver function. In this paper, we summarize the current...

PETACH TIKVA, Israel, May 3, 2017 /PRNewswire/ -Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today provided an update on a Phase II clinical trial to evaluate its liver drug candidate Namodenoson (CF102) in the treatment of non-alcoholic fatty liver disease...

aim : the aim of this study was to review cases of non-alcoholic fatty liver disease (nafld) cases and to determine the prevalence of non-alcoholic fatty liver disease as a cause of elevated alanine aminotransferase (alt) in healthy blood donors in the permian area and also assess risk factors of nafld such as body mass index (bmi) and correlation with metabolic syndrome in these subjects. back...

Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes diseases: 25% population European countries have signs NAFLD, 10–20% patients with steatosis develop an inflammatory process (non-alcoholic steatohepatitis), which, if not treated, can transform into fibrosis and cirrhosis. In people, NAFLD diagnosed, prognosis inaccurate, there are no licensed methods treating disease. ...

The non-alcoholic fatty liver disease is considered a predominant hepatopathy worldwide and a component of metabolic syndrome. It represents a risk factor for the development of cardiovascular diseases, independently of the presence of diabetes mellitus, hypertension and obesity. For this reason, nowadays an epidemiological analysis and a research of the causes that correlate non-alcoholic fatt...

background: non-alcoholic fatty liver disease (nafld) is characterized by fatty change of liver without inflammation. the aim of this study was to evaluate presence of clinical and metabolic components in non-diabetic patients with nafld and to assess the relationship between insulin resistance and these factors. materials andmethods: in this study, a group of 50 sonographically confirmed patie...

OBJECTIVES Effective oral therapies for hepatitis B and C have recently been developed, while there are no approved pharmacological therapies for alcoholic and non-alcoholic fatty liver diseases (ALD and NAFLD). We hypothesise that fewer advances in fatty liver diseases could be related to disparities in research attention. METHODS We developed the Attention-to-Burden Index (ABI) that compare...